3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
31
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Wilms Tumor
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleuropulmonary blastoma
1
Pathologic Complete Response
1
Neurofibrosarcoma
1
Neuroblastoma
1
Interventions
Trastuzumab
5
Carboplatin
5
130-nm albumin-bound paclitaxel
3
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled